ANIP
ANI Pharmaceuticals Inc
74.00$
-0.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 84.6% | 92.3% | 87.3% | 92.3% | 94.4% | 97.4% | 98.6% | 97.6% | 99.3% | 99.2% | 91.0% | 86.2% | 90.7% | 93.0% | 90.7% | 62.3% | 77.2% | 67.5% | 31.9% | 31.9% | 35.5% | 41.1% | 36.9% | 41.7% | 45.3% | 57.5% | 41.1% | 52.3% | |
| 82.4% | 91.3% | 85.2% | 90.4% | 83.1% | 95.5% | 6.6% | 3.2% | 34.2% | 50.1% | 66.5% | 81.9% | 85.2% | 91.7% | 89.7% | 25.0% | 64.1% | 54.2% | 8.5% | 7.6% | 10.0% | 13.6% | 1.7% | 13.0% | 6.3% | 24.4% | 11.3% | 19.8% | |
| 82.4% | 91.3% | 85.2% | 90.4% | 83.1% | 95.5% | 96.9% | 95.1% | 51.2% | 98.1% | 83.6% | 81.9% | 85.2% | 91.7% | 89.7% | 25.0% | 64.1% | 54.2% | 8.5% | 7.6% | 10.0% | 13.6% | 1.7% | 13.0% | 6.3% | 24.4% | 11.8% | 19.8% | |
| – | – | – | – | – | – | – | – | 47.0% | 0.0% | 1.3% | 0.2% | – | – | 14.0% | 28.1% | 6.6% | 7.7% | 14.2% | 14.3% | 15.1% | 15.8% | 20.8% | 16.7% | 21.8% | 17.9% | 17.3% | 19.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | 7.2% | 7.9% | 2.9% | 4.7% | 8.1% | 9.2% | 9.4% | 10.5% | 13.2% | 10.6% | 13.9% | 12.3% | 10.7% | 9.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 1.4% | 0.4% | 10.2% | 2.0% | 2.5% | 3.4% | 5.0% | 8.8% | 8.9% | 8.9% | 6.8% | 5.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 4.1% | 0.7% | 0.6% | 0.6% | 0.4% | 0.8% | 0.8% | 0.8% | 3.6% | 3.7% | 3.1% | 4.7% | 4.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | 0.2% | 23.4% | 16.0% | 23.3% | 54.4% | 55.8% | 46.8% | 39.5% | 40.9% | 38.1% | 33.1% | 23.1% | 42.2% | 33.3% | |
| 23.7% | 5.7% | 30.7% | 18.6% | 21.4% | 9.2% | 10.7% | 28.8% | 19.2% | 4.9% | 21.8% | 56.6% | 57.2% | 39.4% | 27.3% | 8.0% | 47.0% | 43.9% | 47.5% | 57.6% | 54.2% | 53.4% | 57.6% | 53.5% | 55.5% | 49.4% | 66.6% | 62.5% | |
| 23.7% | 5.7% | 30.7% | 18.6% | 21.4% | 9.2% | 10.7% | 27.8% | 19.2% | 4.9% | 21.8% | 10.8% | 18.3% | 11.6% | 27.3% | 8.0% | 5.0% | 4.1% | 9.9% | 9.5% | 38.4% | 13.5% | 17.0% | 11.3% | 13.1% | 16.1% | 15.1% | 19.3% | |
| – | – | 16.3% | – | – | – | – | 6.7% | 1.9% | 2.5% | – | – | 2.5% | – | 20.3% | 3.0% | 40.4% | 39.8% | 37.4% | 0.8% | 26.9% | 2.2% | 2.9% | 0.1% | 0.1% | 0.1% | 0.7% | 1.2% | |
| 2.0% | 1.3% | 1.5% | 1.8% | 8.0% | 2.5% | 6.6% | 11.9% | 2.8% | 2.3% | 18.0% | 6.7% | 10.9% | 5.1% | 2.9% | 3.2% | 1.0% | 0.7% | 1.0% | 0.9% | 2.1% | 3.2% | 2.4% | 3.0% | 3.9% | 4.1% | 3.6% | 4.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 27.8% | 0.0% | 0.0% | 42.0% | 39.8% | 37.4% | 31.1% | 15.6% | 38.5% | 37.4% | 37.1% | 37.6% | 31.5% | 47.9% | 41.6% | |
| 76.3% | 94.3% | 69.3% | 81.4% | 78.6% | 90.8% | 89.3% | 71.2% | 80.8% | 95.1% | 78.2% | 43.4% | 42.8% | 60.6% | 72.7% | 92.0% | 53.0% | 56.1% | 52.5% | 42.4% | 45.8% | 46.6% | 42.4% | 46.5% | 44.5% | 50.6% | 33.4% | 37.5% | |
| -313.0% | -211.1% | -509.9% | -366.5% | -375.2% | -292.9% | -227.4% | -519.0% | -209.6% | -174.4% | -406.7% | -327.8% | -370.0% | -348.3% | -631.8% | -108.9% | -7.5% | -1.5% | -0.9% | -1.0% | 2.7% | 3.8% | -1.1% | -6.2% | -12.8% | -8.9% | -7.8% | -1.6% | |
| 280.7% | 2.4% | 5.2% | 3.6% | 3.5% | 3.2% | 2.7% | 5.6% | 2.7% | 2.3% | 4.3% | 2.6% | 4.1% | 4.4% | 9.4% | 11.4% | 4.2% | 4.1% | 3.6% | 2.8% | 2.7% | 2.6% | 2.6% | 1.6% | 2.1% | 2.0% | 1.5% | 1.5% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.